BACKGROUND:In recent years, the effectiveness of stem cel transplantation in the treatment of spinal cord injury has been validated in animal models, and mesenchymal stem cel transplantation for treatment of spinal cord injury has been studied most widely. Currently, there are a number of relevant clinical studies that have shown a good prospect. OBJECTIVE:To evaluate the efficacy and safety of mesenchymal stem cel transplantation for spinal cord injury in human with a system review. METHODS:PubMed database, EMBASE database, Cochrane Library, ISI Web of knowledge, CBM database, VIP database, CNKI database and Wanfang database were searched from their start year up to July 2015 for relevant randomized clinical trials on the treatment of spinal cord injury with mesenchymal stem cel transplantation. The key words were“spinal cord injury, paraplegia, cel transplantation, transplantation, mesenchymal stem cel , bone marrow transplantation, stem cel , randomized control ed trial”in English and Chinese, respectively. RESULTS AND CONCLUSION:A total of 260 articles were retrieved, including 6 randomized clinical trials (252 cases). In the aspects of ASIA touch sensation score, overal Frankel score and daily life activity training score, the patients undergoing mesenchymal stem cel transplantation were significantly superior to those in the control group (P<0.05). In addition, ASIA motor function score and residual urine volume were also improved in the patients undergoing mesenchymal stem cel transplantation, but there was no statistical difference (P>0.05). Compared with the control group, low fever was more common in the patients undergoing mesechymal stem cel transplantation (P<0.05). Another side effect was lower limb numbness, but there was no difference from the control group (P>0.05). These findings suggest that mesenchymal stem cel transplantation has limited efficacy in the treatment of spinal cord injury and cannot induce severe complications, but there is a need for high-quality randomized control ed trials to prove the efficiency and safety of mesenchymal stem cel transplantation for the treatment of spinal cord injury.

Objective To establish a HPLC method for the assay of sinoporphyrin sodium (DVDMS) in tumor-bearing mouse plasma and to study its pharmacokinetics .Methods The column was Waters XBridge C18 (3 .0 mm × 100 mm ,3 .5μm) . Gradient elution was applied with mobile phase A as the mixture of acetonitrile-methanol (20:80) and B as the aqueous solu-tion of 1％ acetic acid and 0 .1％ triethylamine at flow rate 0 .7 ml/min .The detection wavelength was 380 nm .DVDMS was administrated to tumor-bearing mice by tail vein injection .The blood samples were collected at designated time and centrifuged for plasma .DVDMS in plasma samples were extracted by protein precipitation and analyzed by the HPLC method mentioned a-bove .Pharmacokinetic parameters were calculated by DAS 2 .0 with statistical moment analysis .Results DVDMS showed good linearity within the ranges of 70 .8-14160 ng/ml (r=0 .9998) .The main pharmacokinetic parameters were calculated as follows :cmax = (24127 .59 ± 1415 .23) ng/ml ,tmax =0 .083 h ,t1/2 = (9 .59 ± 1 .25) h ,MRT0-∞ = (11 .77 ± 1 .73) h ,AUC0-∞ =(34775 .83 ± 6185 .43) h · ng/ml .Conclusion This HPLC method is sensitive ,rapid and accurate ,which can be used for a-nalysis and research of DVDMS in plasma samples of tumor-bearing mice .

Objective To explore the potential mechanism of Babao Dan on primary liver cancer based on network pharmacology. Methods First, the diethylnitrosamine-induced hepatocellular carcinoma rat（HCC）model was used to observe the effects of Babao Dan. Then, the effective components in Babao Dan were detected by UPLC-MS, and the potential target sites of these effective components were predicted in the Swiss Target Prediction databases, etc. The corresponding target sites for HCC were screened using GeneCards, OMIM and Therapeutic Target Database, and the common target sites between Babao Dan and HCC were obtained after getting the intersection. The protein-protein interaction network was drawn by Cytoscape software and the STRING database, and the key molecules regulating HCC by Babao Dan were screened out. The effective target sites were subjected to GO analysis in the DAVID database and enrichment analysis in the Pathway’s KEGG. Finally, the clinical relevance of key molecules to liver cancer patients was verified by the TCGA database. Results Babao Dan could slow down the tumor development. 851 chemical components were detected in BaBao Dan by UPLC-MS , 9 major active components and 285 target sites were identified. 637 hepatocellular carcinoma-related targets were screened out, and 16 targets of Babao Dan regulating HCC were identified. GO enrichment analysis showed 802 biological processes, 11 cell compositions, and 43 molecular functions, while KEGG pathway enrichment analysis identified a total of 90 pathways. Correlation analysis of TCGA identified three key molecules associated with the survival of liver cancer patients. Conclusion In the primary rat liver cancer model, Babao Dan was found to significantly prolong the survival of cancer-induced rats and reduce tumor burden. The initial prediction of the mechanism by which Babao Dan regulating liver cancer was made through UPLC-MS analysis and network pharmacology methods, indicating that Babao Dan has the characteristics of multi-component, multi-pathway, and multi-target regulation of primary liver cancer, which could provide a reference for further relevant experimental research.